Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Jacques Goy

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
International Journal of Cardiology|June 4, 2017
Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds: Two-year clinical outcomes of the EVERBIO II trialDiego Arroyo, Gregoire Gendre, Sara Schukraft, et al.
Trials|January 9, 2014
Comparison of everolimus-eluting and biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: study protocol of the randomized controlled EVERBIO II trialDiego Arroyo, Mario Togni, Serban Puricel, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 17, 2014
A propensity score-matched comparison between Cardia and Amplatzer PFO closure devices - insights from the SOLUTION registry (Swiss percutaneOus patent foramen ovale cLosUre in recurrent clinical events prevenTION)Serban Puricel, Diego Arroyo, Jean-Jacques Goy, et al.
Swiss Medical Weekly|November 19, 2020
Impact of first medical contact to revascularisation time on long-term clinical outcomes in ST-segment elevation myocardial infarction patientsOlivier Roux, Andreas Schweighauser, Sara Schukraft, et al.
Texas Heart Institute Journal|July 10, 2024
Predictive Value of HAS-BLED and HEMORR2HAGES Bleeding Risk Scores After Percutaneous Coronary InterventionIanis Doomun, Daphné Doomun, Sara Schukraft, et al.
Frontiers in Cardiovascular Medicine|December 20, 2021
Ischemic and Bleeding Outcomes According to the Academic Research Consortium High Bleeding Risk Criteria in All Comers Treated by Percutaneous Coronary InterventionsDaphné Doomun, Ianis Doomun, Sara Schukraft, et al.
Journal of the American College of Cardiology|February 28, 2015
Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffoldsSerban Puricel, Diego Arroyo, Noé Corpataux, et al.
Swiss Medical Weekly|January 15, 2016
Vascular response to everolimus- and biolimus-eluting coronary stents versus everolimus-eluting bioresorbable scaffolds--an optical coherence tomography substudy of the EVERBIO II trialZacharenia Kallinikou, Diego Arroyo, Mario Togni, et al.
Swiss Medical Weekly|August 30, 2013
Urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL) and contrast-induced acute kidney injury after coronary angiogramTilman Perrin, Eric Descombes, Jean-Luc Magnin, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|March 8, 2008
Outcome after percutaneous closure of a patent foramen ovale using the Intrasept device: a multi-centre studyJustin G L M Luermans, Martijn C Post, Rainer Schräder, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
International Journal of Cardiology|June 4, 2017
Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds: Two-year clinical outcomes of the EVERBIO II trialDiego Arroyo, Gregoire Gendre, Sara Schukraft, et al.
Trials|January 9, 2014
Comparison of everolimus-eluting and biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: study protocol of the randomized controlled EVERBIO II trialDiego Arroyo, Mario Togni, Serban Puricel, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 17, 2014
A propensity score-matched comparison between Cardia and Amplatzer PFO closure devices - insights from the SOLUTION registry (Swiss percutaneOus patent foramen ovale cLosUre in recurrent clinical events prevenTION)Serban Puricel, Diego Arroyo, Jean-Jacques Goy, et al.
Swiss Medical Weekly|November 19, 2020
Impact of first medical contact to revascularisation time on long-term clinical outcomes in ST-segment elevation myocardial infarction patientsOlivier Roux, Andreas Schweighauser, Sara Schukraft, et al.
Texas Heart Institute Journal|July 10, 2024
Predictive Value of HAS-BLED and HEMORR2HAGES Bleeding Risk Scores After Percutaneous Coronary InterventionIanis Doomun, Daphné Doomun, Sara Schukraft, et al.
Frontiers in Cardiovascular Medicine|December 20, 2021
Ischemic and Bleeding Outcomes According to the Academic Research Consortium High Bleeding Risk Criteria in All Comers Treated by Percutaneous Coronary InterventionsDaphné Doomun, Ianis Doomun, Sara Schukraft, et al.
Journal of the American College of Cardiology|February 28, 2015
Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffoldsSerban Puricel, Diego Arroyo, Noé Corpataux, et al.
Swiss Medical Weekly|January 15, 2016
Vascular response to everolimus- and biolimus-eluting coronary stents versus everolimus-eluting bioresorbable scaffolds--an optical coherence tomography substudy of the EVERBIO II trialZacharenia Kallinikou, Diego Arroyo, Mario Togni, et al.
Swiss Medical Weekly|August 30, 2013
Urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL) and contrast-induced acute kidney injury after coronary angiogramTilman Perrin, Eric Descombes, Jean-Luc Magnin, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|March 8, 2008
Outcome after percutaneous closure of a patent foramen ovale using the Intrasept device: a multi-centre studyJustin G L M Luermans, Martijn C Post, Rainer Schräder, et al.
Pageof 6